Daiichi-Sankyo Consolidates In Europe

Japan's Daiichi-Sankyo is to redouble efforts to expand in Europe. Sankyo alone had sales of EUR322mn (US$406mn) in the region last year. With over 1,000 sales representatives already employed in the region, the company also hopes to benefit from a new co-marketing deal on US firm Eli Lilly's osteoporosis treatment Evista (raloxifene). The arrangement, which marks a new area of therapeutic focus for the Japanese company, will cover the major Western European markets except France, Spain and the

To read the full article, please take a trial.